MJFF awards $1.35M to Rhythm for Phase 2 clinical trial of RM-131 for Parkinson's disease

NewsGuard 100/100 Score

Rhythm announced today that The Michael J. Fox Foundation for Parkinson's Research (MJFF) has awarded a $1.35 million research grant to Rhythm to help fund a Phase 2 clinical trial of RM-131, the company's novel ghrelin agonist, for the treatment of refractory constipation in patients with Parkinson's disease (PD). This study expands the ongoing Phase 2 clinical program for RM-131 for the treatment of both upper and lower gastrointestinal (GI) functional disorders.

"As we work toward a cure for Parkinson's, alleviating the symptoms of disease is our best approach to improve quality of life for the millions living with PD. Development of a treatment for painful and debilitating constipation will have significant meaning to this population," said Maurizio Facheris, MD, MJFF associate director of research programs.

Constipation is common among people with Parkinson's, with studies reporting more than 50% of PD patients suffering from moderate to severe constipation. Many of these patients are refractory to existing therapy. In addition, GI dysfunction in PD can affect the upper GI tract, resulting in gastroparesis. Overall, the symptoms of upper and lower GI functional disorders can be debilitating and disruptive to the lives of PD patients and, in addition, may undermine the GI absorption of L-DOPA in the intestine, interfering with this drug's effectiveness. Approximately one million people in the U.S. are living with Parkinson's disease.

"Refractory constipation is a significant issue in Parkinson's disease, and this first study of RM-131 in Parkinson's patients is focused on this disorder," said Keith Gottesdiener, MD, CEO of Rhythm. "As we continue our work to advance RM-131 in the clinic, we are excited to join with The Michael J. Fox Foundation to address this important unmet need in Parkinson's disease."

Source:

Rhythm

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Landmark study confirms five key Parkinson's Disease variants in largest meta-analysis